ScinoPharm Taiwan Ltd.
Products and ServicesQuality and ComplianceScinoPharm ChinaAbout ScinoPharmInvestor Relations
 
  Biotechnology
   
 
  Product List

Technical Services

Manufacturing

Biotechnology

  Products & Capabilities
 



 

 


Products & Capabilities

ScinoPharm is expanding its chemistry-based API business into the biopharmaceutical area. ScinoPharm’s Biotech group has developed the cell lines and process technologies for the following recombinant proteins.

  • Erythropoietin
  • G-CSF and PEGylated G-CSF
  • Human Growth Hormone
  • Interferon α-2b and PEGylated Interferon α-2b
  • Interferon β-1b
  • Recombinant Aprotinin
  • TNFR-Fc (Etanercept)
  • Vascular Endothelial Growth Factor (VEGF)
  • Brain Derived Neurotrophic Factor (BDNF)


  •  

    ScinoPharm is currently focusing on development of cell lines and process technologies for more than 10 biosimilars of monoclonal antibodies, including:

    • Trastuzumab
    • Bevacizumab
    • Rituximab
    • Cetuximab
    • Adalimumab

    ScinoPharm over the years has established the following core expertise and capabilities:

    • Gene cloning
    • Protein expression
    • Fermentation and cell culture
    • Recovery and purification
    • Product characterization
    • Bioassay

    On protein expression, ScinoPharm has considerable experiences in E. coli, Pichia, and CHO systems. Furthermore, ScinoPharm has developed platform technologies for screening and selection of high producing clones for production of biosimilar monoclonal antibodies.


     

     




    Sitemap | Legal Notices and Privacy Statements | © ScinoPharm® Taiwan, Ltd. All Rights Reserved.